Argus Investors Counsel Inc. Raises Holdings in Boston Scientific Corporation $BSX

Argus Investors Counsel Inc. increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 1.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 26,863 shares of the medical equipment provider’s stock after acquiring an additional 415 shares during the period. Boston Scientific makes up about 2.0% of Argus Investors Counsel Inc.’s investment portfolio, making the stock its 16th largest position. Argus Investors Counsel Inc.’s holdings in Boston Scientific were worth $2,885,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. 1248 Management LLC bought a new stake in Boston Scientific during the first quarter worth about $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific during the 1st quarter valued at approximately $27,000. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Boston Scientific during the second quarter worth approximately $37,000. Activest Wealth Management boosted its holdings in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 373 shares in the last quarter. Finally, Ransom Advisory Ltd purchased a new position in Boston Scientific in the 1st quarter worth about $43,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Price Performance

Shares of BSX opened at $98.20 on Friday. The firm has a market cap of $145.51 billion, a PE ratio of 58.45, a P/E/G ratio of 2.36 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The firm has a fifty day simple moving average of $103.79 and a two-hundred day simple moving average of $102.11.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company’s revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BSX shares. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Leerink Partners started coverage on Boston Scientific in a research report on Monday, June 16th. They issued an “outperform” rating and a $118.00 target price for the company. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. UBS Group increased their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Finally, Wells Fargo & Company increased their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $118.17.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.